Cellino Intro

Nabiha Saklayen, PhD Co-Founder & CEO nsaklayen@cellinobio.com



СЕШПО

0

EVERY HUMAN. EVERY CELL.

Autologous Cell Therapies at Scale

Mission

Build the leading platform for precision manufacturing of regenerative therapies

Vision


Unlock regenerative medicine for hundreds of millions of patients

*exact locations will depend on cell type and partner needs






Cellino's Proprietary Engine Industrializes Artisanal Processes






An Optical Approach to Cell Engineering is Precise and Scalable



BEFORE LASER AFTER LASER


Laser Editing - Proprietary






We Use Multimodal Datasets to Enhance Human Decisions

Cellino-owned infrastructure and algorithms



Platform Designed to Deliver Cell Products Near Patients



First Clinical Products on Platform

Product	Disease	Global Patient Population	Clinical Collaborator
iPSC – induced Pluripotent Stem Cells	Starting material for most regenerative therapies		NIH
RPE – Retinal Pigment Epithelial Cells	Age-related Macular Degeneration	288M	NIH
DOPA – Dopaminergic Neurons	Parkinson's	7M	TBD

000000

000000